Literature DB >> 3031172

Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients.

A Hagenbeek, G J Brummelhuis, A Donkers, A M Dumas, A ten Haaft, B J Schaap, W Sizoo, B Löwenberg.   

Abstract

We studied the kinetics of the disappearance of CMV-specific IgG from the serum of 18 allogeneic bone marrow transplant recipients who were receiving repeated intravenous infusions of immunoglobulin. Peak serum titers occurred 24-48 hr after infusion. The mean half-life of IgG to CMV varied from 30 to 70 hr. Additional studies showed that this unexpectedly short half-life was not specific for either the preparation used or the type of patient studied. Repeated treatment did not prevent patients from developing CMV infections (incidence, 50%); however, none of the patients developed CMV interstitial pneumonitis. Treatment had to be discontinued for one patient because of a serum sickness-like syndrome. Our results suggest that rational, time-sequential passive immunization regimens should be developed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3031172     DOI: 10.1093/infdis/155.5.897

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Bryan T Alexander; Lindsay M Hladnik; Kristan M Augustin; Ed Casabar; Peggy S McKinnon; Richard M Reichley; David J Ritchie; Peter Westervelt; Erik R Dubberke
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

3.  Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation.

Authors:  P A Thürmann; C Sonnenburg-Chatzopoulos; R Lissner
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 4.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 5.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay.

Authors:  S L Nielsen; I Sørensen; H K Andersen
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

Review 7.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.